Milven (Venlafaxine)

Venlafaxine, the active ingredient in Milven, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as an oral tablet for systemic use. It is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder in adult patients. It is approved for use in the European Union market.

GNH USA supplies Milven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Venlafaxine is an SNRI used to treat several mood and anxiety disorders. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Generalized anxiety disorder: reduces excessive worry and associated physical symptoms. - Social anxiety disorder: diminishes fear of social situations and improves functioning. - Panic disorder: decreases frequency and severity of panic attacks.

Venlafaxine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness. - Insomnia: difficulty falling or staying asleep. - Sweating: increased perspiration. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Suicidal thoughts: emergence of suicidal ideation, especially in early treatment. - Severe liver injury: rare hepatotoxicity. - Allergic reactions: rash, angioedema, or anaphylaxis. - Cardiac arrhythmia: abnormal heart rhythm.

When prescribing Venlafaxine, clinicians should consider several safety considerations. - Cardiovascular assessment: monitor blood pressure and heart rate, especially at higher doses. - Psychiatric monitoring: observe for worsening depression or emergence of suicidal thoughts. - Drug discontinuation: taper gradually to avoid withdrawal symptoms. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Drug interactions: review concomitant serotonergic agents to reduce risk of serotonin syndrome. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Venlafaxine can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, tramadol): increased serotonin syndrome risk. - CYP2D6 inhibitors (e.g., quinidine, paroxetine): can raise venlafaxine plasma levels. - NSAIDs or anticoagulants: heightened bleeding risk. - Thioridazine: may cause QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce venlafaxine exposure. - Antihypertensives: additive blood pressure lowering effect. - Alcohol: may enhance CNS depression. - Diuretics: potential for electrolyte imbalance. - Lithium: monitor for additive neuropsychiatric effects.